361 research outputs found
Tutorial in oral antithrombotic therapy: Biology and dental implications
Objectives: Recent developments of new direct oral anticoagulants that target specific clotting factors necessitate
understanding of coagulation biology. The objective of this tutorial is to offer dental
professionals a review of
coagulation mechanisms and the
pharmacodynamics of the conventional and new oral anticoagulants. Also, we
summarized the dental implications of the conventional and new anticoagulants.
Method
: We searched Medline using search terms "antithrombotic", "antihemostasis" or "anticoagulation" and
combined them with the search results of "dental", "oral surgery" or "periodontal". We restricted the results to
"human" and "English".
Results: The early coagulation cascade, the new cell-based coagulation model, the
pharmacokinetics and
pharmacodynamics of conventional antithrombotics, and new oral anticoagulants were reviewed. The new direct factor
Xa inhibitors and the direct thrombin inhibitor (s), called direct oral anticoagulants (DOAs) have rapid onset of
action, fast elimination on cessation, and fewer drug-drug or drug-food interactions than warfarin. However, the
lack of antidotes raises concerns that some dental
procedures may trigger serious hemorrhagic events. Additionally, careful
perioperative withdrawal and resumption
protocols for the DOAs are reviewed, because DOAs' blood
levels are dependent on renal function. Also, various reversal strategies in the event of excessive bleedings are
summarized. Perioperative management of dental
patients taking new DOAs and conventional oral anticoagulants
are also discussed. However, the
perioperative strategies for DOAs are yet to be validated in randomized trials
Nurses\u27 Alumnae Association Bulletin, June 1967
President\u27s Message
Officers and Committee Chairman
Financial Report
Report to Alumnae Association
Nursing Service Report
Operating Room Report
School of Practical Nursing Report
School of Nursing Report
President Herbert\u27s Address (abstracted)
Report from Africa
Student Activities
Nursing Service Staff Association
Resume of Alumnae Meetings
Way and Means Report
Social Committee
Building Fund Report
Class News
Notice
Recommended from our members
Interdot Lead Halide Excess Management in PbS Quantum Dot Solar Cells
Light-harvesting devices made from lead sulfide quantum dot (QD) absorbers are one of the many promising technologies of third-generation photovoltaics. Their simple, solution-based fabrication, together with a highly tunable and broad light absorption makes their application in newly developed solar cells, particularly promising. In order to yield devices with reduced voltage and current losses, PbS QDs need to have strategically passivated surfaces, most commonly achieved through lead iodide and bromide passivation. The interdot spacing is then predominantly filled with residual amorphous lead halide species that remain from the ligand exchange, thus hindering efficient charge transport and reducing device stability. Herein, it is demonstrated that a post-treatment by iodide-based 2-phenylethlyammonium salts and intermediate 2D perovskite formation can be used to manage the lead halide excess in the PbS QD active layer. This treatment results in improved device performance and increased shelf-life stability, demonstrating the importance of interdot spacing management in PbS QD photovoltaics
C5 Palsy After Cervical Spine Surgery: A Multicenter Retrospective Review of 59 Cases.
STUDY DESIGN: A multicenter, retrospective review of C5 palsy after cervical spine surgery.
OBJECTIVE: Postoperative C5 palsy is a known complication of cervical decompressive spinal surgery. The goal of this study was to review the incidence, patient characteristics, and outcome of C5 palsy in patients undergoing cervical spine surgery.
METHODS: We conducted a multicenter, retrospective review of 13 946 patients across 21 centers who received cervical spine surgery (levels C2 to C7) between January 1, 2005, and December 31, 2011, inclusive. P values were calculated using 2-sample t test for continuous variables and χ(2) tests or Fisher exact tests for categorical variables.
RESULTS: Of the 13 946 cases reviewed, 59 patients experienced a postoperative C5 palsy. The incidence rate across the 21 sites ranged from 0% to 2.5%. At most recent follow-up, 32 patients reported complete resolution of symptoms (54.2%), 15 had symptoms resolve with residual effects (25.4%), 10 patients did not recover (17.0%), and 2 were lost to follow-up (3.4%).
CONCLUSION: C5 palsy occurred in all surgical approaches and across a variety of diagnoses. The majority of patients had full recovery or recovery with residual effects. This study represents the largest series of North American patients reviewed to date
Prospectus, December 10, 1986
https://spark.parkland.edu/prospectus_1986/1033/thumbnail.jp
World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs
The proliferation of antimalarial drug trials in the last ten years provides the opportunity to launch a concerted global surveillance effort to monitor antimalarial drug efficacy. The diversity of clinical study designs and analytical methods undermines the current ability to achieve this. The proposed World Antimalarial Resistance Network (WARN) aims to establish a comprehensive clinical database from which standardised estimates of antimalarial efficacy can be derived and monitored over time from diverse geographical and endemic regions. The emphasis of this initiative is on five key variables which define the therapeutic response. Ensuring that these data are collected at the individual patient level in a consistent format will facilitate better data management and analytical practices, and ensure that clinical data can be readily collated and made amenable for pooled analyses. Such an approach, if widely adopted will permit accurate and timely recognition of trends in drug efficacy. This will guide not only appropriate interventions to deal with established multidrug resistant strains of malaria, but also facilitate prompt action when new strains of drug resistant plasmodia first emerge. A comprehensive global database incorporating the key determinants of the clinical response with in vitro, molecular and pharmacokinetic parameters will bring together relevant data on host, drug and parasite factors that are fundamental contributors to treatment efficacy. This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.
PURPOSE: Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER)-positive metastatic breast cancers include, among others, ER loss and acquired activating mutations in the ligand-binding domain of the ER gene (ESR1LBDm). ESR1 mutational mediated resistance may be overcome by selective ER degraders (SERD). During the first-in-human study of oral SERD AZD9496, early changes in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) were explored as potential noninvasive tools, alongside paired tumor biopsies, to assess pharmacodynamics and early efficacy. EXPERIMENTAL DESIGN: CTC were enumerated/phenotyped for ER and Ki67 using CellSearch in serial blood draws. ctDNA was assessed for the most common ESR1LBDm by droplet digital PCR (BioRad). RESULTS: Before starting AZD9496, 11 of 43 (25%) patients had ≥5 CTC/7.5 mL whole blood (WB), none of whom underwent reduction to <5 CTC/7.5 mL WB on C1D15. Five of 11 patients had baseline CTC-ER+, two of whom had CTC-ER+ reduction. CTC-Ki67 status did not change appreciably. Patients with ≥5 CTC/7.5 mL WB before treatment had worse progression-free survival (PFS) than patients with <5 CTC (P = 0.0003). Fourteen of 45 (31%) patients had ESR1LBDm + ctDNA at baseline, five of whom had ≥2 unique mutations. Baseline ESR1LBDm status was not prognostic. Patients with persistently elevated CTC and/or ESR1LBDm + ctDNA at C1D15 had worse PFS than patients who did not (P = 0.0007). CONCLUSIONS: Elevated CTC at baseline was a strong prognostic factor in this cohort. Early on-treatment changes were observed in CTC-ER+ and ESR1LBDm + ctDNA, but not in overall CTC number. Integrating multiple biomarkers in prospective trials may improve outcome prediction and ET resistance mechanisms' identification over a single biomarker
- …